For the quarter ending 2025-09-30, ATRA had -$11,161K decrease in cash & cash equivalents over the period. -$9,787K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -4,303 | 40,397 |
| Stock-based compensation expense | 1,225 | 7,010 |
| Depreciation and amortization expense | 36 | 2,031 |
| Accretion of liability related to sale of future revenues | 891 | 1,809 |
| Amortization (accretion) of investment premiums (discounts) | 83 | -258 |
| Non-cash operating lease expense | 320 | 4,413 |
| Loss on impairment of lease right-of-use asset | 0 | 4,130 |
| Gain on derecognition of lease liabilities | 0 | 1,167 |
| Other non-cash items, net | 4 | 547 |
| Accounts receivable | 1,913 | -1,482 |
| Inventories | 0 | -10,655 |
| Other current assets | 367 | -6,211 |
| Other assets | -46 | 4 |
| Accounts payable | -983 | -3,066 |
| Accrued compensation | -485 | -4,037 |
| Accrued research and development expenses | -629 | -7,013 |
| Other current liabilities | -2,239 | -1,438 |
| Deferred revenue | -596 | -93,485 |
| Operating lease liabilities | -711 | -4,190 |
| Other long-term liabilities | 0 | 1 |
| Net cash used in operating activities | -9,787 | -35,456 |
| Purchases of short-term investments | 2,466 | 5,419 |
| Proceeds from maturities and sales of short-term investments | 1 | 17,199 |
| Purchases of property and equipment | 0 | 0 |
| Proceeds from sale of property and equipment | 44 | 349 |
| Net cash provided by investing activities | -2,421 | 12,129 |
| Proceeds from sale of pre-funded warrants to purchase common stock in an underwritten registered direct offering or registered direct offering, net | -461 | 15,304 |
| Proceeds from issuance of common stock through atm facilities, net | 1,496 | 0 |
| Taxes paid related to net share settlement of restricted stock units | - | 0 |
| Proceeds from employee stock awards | 12 | 1 |
| Principal payments on finance lease obligations | 0 | 250 |
| Other financing activities, net | 0 | -1 |
| Net cash provided by financing activities | 1,047 | 15,054 |
| Increase (decrease) in cash, cash equivalents and restricted cash | -11,161 | -8,273 |
| Cash and cash equivalents at beginning of period | 25,176 | - |
| Cash and cash equivalents at end of period | 5,742 | - |
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)